Immunogenic cell death

Replimune to Host Virtual Investor Event on December 7, 2022

Retrieved on: 
Tuesday, November 22, 2022
MOA, Skin cancer, Immunogenic cell death, TME, RP2, Safety, Melanoma, Patient, Neoplasm, Tumor microenvironment, RP1, Bristol Myers Squibb, Nivolumab, Webcast, RP3, RPX, Antigen, Pharmaceutical industry

Additionally, the company will review the commercial opportunity in skin cancer with RP1.

Key Points: 
  • Additionally, the company will review the commercial opportunity in skin cancer with RP1.
  • The Company will also provide an update on its RP2 and RP3 program.
  • The event will begin at 8:00 a.m. Eastern Time on Wednesday, December 7, 2022.
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.

Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting

Retrieved on: 
Friday, November 18, 2022
Doctor of Philosophy, Immunogenic cell death, Glioblastoma, Therapy, Brain, Patient, Virulence, Data, Society, Neoplasm, Tumor microenvironment, Injection, SNO, Disease, MD, HSV, CADL, Nestin, Cancer, Form, Pakistan Society of Neuro-Oncology, Content discovery platform, Clinical trial, Survival, Biology, Pharmaceutical industry, Vaccine, Fellow of the Academy of Medical Sciences, Candel

An overview of this data will be presented in-person at the Society for Neuro-Oncology (SNO) 27th Annual Meeting today starting at 5:30 pm ET in Tampa, Florida.

Key Points: 
  • An overview of this data will be presented in-person at the Society for Neuro-Oncology (SNO) 27th Annual Meeting today starting at 5:30 pm ET in Tampa, Florida.
  • Data will be reported from 41 patients who were administered CAN-3110, with 40 patients having received a single injection and one patient having received two injections.
  • Diversity of the T cell receptor repertoire after CAN-3110 administration was reported to be associated with overall survival.
  • The effects of multiple doses of CAN-3110 in recurrent glioblastoma are currently being evaluated in an ongoing phase 1 clinical trial.

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 16, 2022
Protide, Immunogenic cell death, PD-1, NSCLC, Docetaxel, Oxaliplatin, European Society for Medical Oncology, Large-cell lung carcinoma, Melanoma, Patient, Neoplasm, Adenocarcinoma, Pembrolizumab, Oncology, Irinotecan, Thymidylate synthase, NCNA, Commencement (album), Security (finance), ESMO, Colorectal cancer, Cancer, Therapy, Pemetrexed, Bevacizumab, Organic acid, Pharmaceutical industry, Medical imaging, Food delivery

EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

Key Points: 
  • EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
  • As of September 30, 2022, NuCana had cash and cash equivalents of 50.8 million compared to 46.5 million as of June 30, 2022 and 60.3 million at December 31, 2021.
  • NuCana continues to advance its various clinical programs and reported a net loss of 4.5 million for the quarter ended September 30, 2022, as compared to a net loss of 8.0 million for the quarter ended September 30, 2021.
  • Basic and diluted loss per share was 0.09 for the quarter ended September 30, 2022, as compared to 0.15 per share for the quarter ended September 30, 2021.

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

Retrieved on: 
Friday, November 11, 2022
GTR, Form, Cytokine, Nivolumab, SITC, Content discovery platform, Company, Gamma ray, Biology, Prostate cancer, MD, Combination therapy, Private Securities Litigation Reform Act, Therapy, Cancer, HSV, Immunotherapy, GLOBE, Doctor of Philosophy, Patient, STR, SEC, CXCL11, Chemokine, CADL, Neoplasm, Tumor microenvironment, MOS, MGMT, Pancreatic cancer, Large-cell lung carcinoma, Immunogenic cell death, Nasdaq, Pharmaceutical industry, Vaccine, Fellow of the Academy of Medical Sciences, Candel

Data were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancer (SITC) today in Boston.

Key Points: 
  • Data were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancer (SITC) today in Boston.
  • Proteomic analysis by OLINK revealed an increase in pro-inflammatory cytokines, including interferon-gamma, the chemokines CXCL9/10 and CXCL11, MCP-1, MCP-3, and granzyme A.
  • Systemic immune activation was observed after the single administration of CAN-2409, prior to initiation of nivolumab (week 3 post treatment).
  • The data support the potential therapeutic synergies between CAN-2409 in combination with immune checkpoint inhibitors across various solid tumors.

Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types

Retrieved on: 
Thursday, November 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, ICD, B cell, Immunotherapy, Neoplasm, GBM, Technology, Mouse, Glioblastoma, Doctor of Philosophy, Immunogenic cell death, Synthetic control method, Survival, SITC, Lymph, Liver, Society for Immunotherapy of Cancer, 23rd Street station (IND Eighth Avenue Line), Cell death, Pharmaceutical industry, Vaccine

These new data provide further evidence of the unique mechanism of our immunotherapy platform and its potential applicability in a wide variety of tumor types beyond glioblastoma, where we have compelling clinical data, said Mark A. Exley, Ph.D., Chief Scientific Officer.

Key Points: 
  • These new data provide further evidence of the unique mechanism of our immunotherapy platform and its potential applicability in a wide variety of tumor types beyond glioblastoma, where we have compelling clinical data, said Mark A. Exley, Ph.D., Chief Scientific Officer.
  • These data support our lead program, IGV-001, which combines personalized, autologous, whole-tumor derived cells with an antisense oligonucleotide in implantable biodiffusion chambers.
  • These data suggest a potential mechanism of action of IGV-001 in GBM via ICD stimulation of an antitumor immune response.
  • The second poster presentation on November 11, 2022, provides evidence for the broad, systemic, and durable antitumor activity of Imvaxs platform.

Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Head, Metastasis, Annual general meeting, Immunotherapy, SGN, Enfortumab vedotin, Technology, Large-cell lung carcinoma, Seagen, Immunogenic cell death, HNSCC, Safety, Inc., Senior, ESCC, Cancer, Disease, ADC, Patient, Esophageal cancer, Society, SITC, Trial of the century, Pharmaceutical industry, Vaccine, NSCLC

Seagen Inc. (Nasdaq: SGEN) today announced that data from the companys diverse pipeline of targeted cancer therapy candidates will be presented at the Society for Immunotherapy of Cancers (SITC) Annual Meeting being held November 8-12 in Boston.

Key Points: 
  • Seagen Inc. (Nasdaq: SGEN) today announced that data from the companys diverse pipeline of targeted cancer therapy candidates will be presented at the Society for Immunotherapy of Cancers (SITC) Annual Meeting being held November 8-12 in Boston.
  • The presentations highlight data from multiple ongoing clinical and preclinical research studies that employ Seagens proprietary antibody-drug conjugate (ADC) technology, as well as other novel cancer targeting approaches.
  • "Seagen has a deep heritage in pioneering first-in-class antibody-drug conjugates.
  • Participants had received a median of 3 lines of therapy for metastatic disease prior to enrollment in the study.

Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO

Retrieved on: 
Monday, November 7, 2022
Company, Virus, Private Securities Litigation Reform Act, Content discovery platform, Biology, GLOBE, HSV, SNO, Therapy, Nasdaq, Immunogenic cell death, Immunotherapy, CADL, SEC, Society, SITC, Patient, Cancer, Vaccine, Candel

NEEDHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced new clinical data will be presented in the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA and the 27th Annual Meeting of the Society for Neuro-Oncology (SNO) in Tampa Bay, FL.

Key Points: 
  • NEEDHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced new clinical data will be presented in the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA and the 27th Annual Meeting of the Society for Neuro-Oncology (SNO) in Tampa Bay, FL.
  • CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.
  • TheenLIGHTEN Discovery Platform is the first systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Replimune to Present at Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 2, 2022
MOA, Safety, GLOBE, TME, RPX, Immunogenic cell death, NASDAQ, Neoplasm, Tumor microenvironment, Antigen, Pharmaceutical industry, Vaccine

Replimunes proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.

Key Points: 
  • Replimunes proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.
  • The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response.
  • This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options.
  • For more information, please visit www.replimune.com .

Candel Therapeutics Upcoming Investor Conference Participation for November

Retrieved on: 
Tuesday, November 1, 2022
Content discovery platform, MD, Immunogenic cell death, Doctor of Philosophy, SEC, Cancer, GLOBE, Virus, Nasdaq, HSV, Private Securities Litigation Reform Act, Company, Therapy, Patient, Biology, CADL, Online shopping, Vaccine, Fellow of the Academy of Medical Sciences, Candel

NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November:

Key Points: 
  • NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November:
    To access the webcast recordings following the event, please visit the Candel Therapeutics website at https://ir.candeltx.com/news-and-events/events-and-presentations.
  • CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.
  • TheenLIGHTEN Discovery Platform is the first systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models

Retrieved on: 
Wednesday, October 26, 2022
SEC, Company, University, Virus, Penn, Science Publishing Group, MD, Doctor of Philosophy, Private Securities Litigation Reform Act, Nasdaq, Cancer, Center, Intellectual property, Tumor microenvironment, Patient, Pathology, Medical laboratory, HSV, Immunogenic cell death, GLOBE, Enlightenment, Therapy, Transgene, Perelman School of Medicine at the University of Pennsylvania, Biology, Content discovery platform, Partnership, CADL, Vaccine, Fellow of the Academy of Medical Sciences, Candel, Immunotherapy

Herpes simplex virus (HSV) vectors containing selected transgenes based on Candel's enLIGHTEN Discovery Platform will be evaluated in combination with investigational CAR-T cell therapies in tumor models.

Key Points: 
  • Herpes simplex virus (HSV) vectors containing selected transgenes based on Candel's enLIGHTEN Discovery Platform will be evaluated in combination with investigational CAR-T cell therapies in tumor models.
  • Under the terms of the agreement, the parties will collaborate to use novel engineered viruses that break down barriers to CAR-T therapies and to evaluate the effects of these combinations in tumor models.
  • Candel is a clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies.
  • Candel has established two viral immunotherapy platforms based on novel, genetically modified adenovirus and HSV constructs, respectively.